St. Jude Children's Research Hospital

Ting Therapeutics LLC

Creighton University

St. Jude Children's Research Hospital, Inc. (tennessee Not for Profit Corporation)

Jian Zuo

Taosheng Chen

Jaeki Min

Tal Teitz

R Kiplin Guy

Marisa Laura Zallocchi

Tetsuji Yamashita

Santanu Hati

Fei Zheng

Tai Teitz

Zhuo Li

Goktug Asli

Fang Jie

Min Jaeki

Chen Taosheng

Jeff North

Zoe Kellard

Asli Goktug

Pezhman Salehi Dermanaki

Robert Hazlitt

Jie Fang

Bradley Walters

Bryan Kuo

Brandon Walters

Wanda Layman

In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods and compositions for the prevention and treatment of hearing loss

In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-S,6-dihydropyridin-2(1H)-one and derivatives exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice. In one aspect, (E)-1-(3-(3,4,5-trimethoxy phenyl)acryloyl)-S,6-dihydropyridin-2(1H)-one and derivatives can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Compositions and methods for the prevention and treatment of hearing loss

Oseltamivir is used as active agent to treat a hearing impairment and to prevent a hearing impairment, and a method of treating and/or preventing hearing impairments or disorders using Oseltamivir are disclosed. Oseltamivir exhibits excellent protection against noise-induced hearing loss and against cisplatin-induced hearing loss.

Methods for the prevention and treatment of hearing loss using Oseltamivir

Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.

Compositions and methods for prevention and treatment of hearing loss

Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of cisplatin- or noise-induced hearing loss. In one aspect, use of compounds as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods for the prevention and treatment of hearing loss

In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. Momelotinib and Fedratinib exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice when administered prophylactically. In one aspect, Momelotinib or Fedratinib can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Provided are CDK2-PROTAC compounds and pharmaceutical compositions thereof that can be used for specific degradation of the cyclin-dependent kinase 2 (CDK2) protein, for treatment of cancers and other CDK2 related diseases as well as for prevention and treatment of hearing loss.

Compositions, use, and method for CDK2-PROTACs for cancer therapy and hearing loss

Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.

Methods and compositions using a nucleic acid molecule encoding an atonal-associated factor in combination with a co-transcription factor and/or inhibitor of a gene silencing complex to change the sensory perception of an animal are described.

Combination therapy for treating disorders of the ear

In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising &#x3b2;-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Growing community of inventors

Memphis, TN, United States of America

Jian Zuo